Premium
Intrafamilial clinical variability in individuals carrying the CHCHD 10 mutation Gly66Val
Author(s) -
Pasanen P.,
Myllykangas L.,
Pöyhönen M.,
KiuruEnari S.,
Tienari P. J.,
Laaksovirta H.,
Toppila J.,
Ylikallio E.,
Tyynismaa H.,
Auranen M.
Publication year - 2016
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.12470
Subject(s) - mutation , genetics , psychology , biology , medicine , gene
Objectives Mutations in the CHCHD 10 gene, which encodes a mitochondrially targeted protein, have emerged as an important cause of motor neuron disease and frontotemporal lobar degeneration. The aim of this study was to assess the clinical variability in a large family carrying the p.Gly66Val mutation of the CHCHD 10 gene. This mutation has recently been reported to cause late‐onset spinal muscular atrophy ( SMAJ ) or sensorimotor axonal Charcot–Marie–Tooth neuropathy ( CMT 2) in the Finnish population. Materials and methods Nine affected members of an extended Finnish pedigree were included in the study. Detailed clinical and neurophysiological examinations were performed. The CHCHD 10 p.Gly66Val mutation was examined by Sanger sequencing. Results The heterozygous p.Gly66Val mutation was present in all affected individuals from whom a DNA sample was available. The clinical phenotype varied from proximal sensorimotor neuropathy to spinal muscular atrophy and in one case resembled motor neuron disease ALS at its early stages. The age of onset varied from 30 to 73 years. Conclusions Our data demonstrate that even within the same family, the p.Gly66Val variant can cause variable phenotypes ranging from CMT 2‐type axonal neuropathy to spinal muscular atrophy, which may also present as an ALS ‐like disease. The spectrum of CHCHD 10 ‐related neuromuscular disease has widened rapidly, and we recommend keeping the threshold for genetic testing low particularly when dominant inheritance or mitochondrial pathology is present.